Conference Report

Modulating the Autoimmune Response in Type 1 Diabetes: A Report on the 64th Scientific Sessions of the ADA, June 2004, Orlando, FL, USA

Peter Achenbach, Martin Füchtenbusch

Keywords: immunomodulation, immunotherapy, tolerance, Treg cells, type 1 diabetes

Abstract

Type 1 diabetes mellitus results from a loss of insulin-producing β-cells in the pancreatic islets caused by an immune-mediated chronic destructive process. It is generally believed that immune tolerance to β-cells is broken by environmental factors in genetically susceptible individuals, leading to β-cell destruction that is mediated by T lymphocytes. A key assumption in the current pathogenic concept of type 1 diabetes is a defective immunoregulation affecting both central and peripheral mechanisms of tolerance induction against β-cell antigens. In animal models of type 1 diabetes, disease-protective modulation of the islet autoimmune response can be effected by various strategies including administration of islet antigens. In human type 1 diabetes, therefore, new strategies are currently being developed with the aim of actively suppressing the autoimmune process and inducing a lasting tolerance against islet antigens. In this context, inducing regulatory T cells in vivo (i.e. CD4⁺CD25⁺ T cells or type 1 regulatory T cells) is currently becoming more widespread. The following report highlights some of the recent studies on immunotherapy of type 1 diabetes, presented at the 64^th Scientific Sessions, held in June 2004, in Orlando, Florida.

Fulltext: HTML , PDF (174KB)

This article has been cited by other articles:

	Effect of Displaying P277 Peptide on Surface of L-asparaginase on Its Antigenicity and Efficacy of Autoimmune Diabetes Prevention in NOD Mice Zhu AH, Liu WT, Long J, Wu J, Liu JJ, Li TM Chinese Journal of Biochemistry and Molecular Biology 2007. 23(9):730-737